REDWOOD CITY, Calif., May 4, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cell (CSC) and immuno-oncology pathways, will announce financial results for the quarter ended March 31, 2015 on Thursday, May 7, 2015 after the close of U.S.-based financial markets. Paul J. Hastings, Chairman and Chief Executive Officer, will host a conference call to review the results beginning at 1:30 p.m. Pacific Time (PT)/4:30 p.m. Eastern Time (ET).
Analysts and investors can participate in the conference call by dialing 855-420-0692 for domestic callers and 484-756-4194 using the conference ID# 41468811.
The press release and an audio-only webcast of the conference call will be accessible through a link in the Investor Relations section of the OncoMed website: http://www.oncomed.com. The web broadcast of the conference call will be available for replay through May 22, 2015.
About OncoMed Pharmaceuticals
OncoMed Pharmaceuticals is a clinical-stage company focused on discovering and developing novel therapeutics targeting cancer stem cell (CSC) and immune-oncology pathways. OncoMed has six anti-cancer product candidates in clinical development, the most advanced of which are in randomized Phase 2 clinical trials. Demcizumab (anti-DLL4, OMP-21M18), tarextumab (anti-Notch2/3, OMP-59R5), brontictuzumab (anti-Notch1, OMP-52M51), anti-DLL4/VEGF bispecific antibody (OMP-305B83), vantictumab (anti-FZD7, OMP-18R5), and ipafricept (FZD8-Fc, OMP-54F28) each target key cancer stem cell signaling pathways including Notch and Wnt. OncoMed recently filed an Investigational New Drug application for anti-RSPO3 (OMP-131R10), an antibody targeting a third key cancer stem cell signaling pathway called R-spondin-LGR. OncoMed is also pursuing discovery of additional novel anti-CSC and cancer immuno-oncology product candidates. OncoMed has formed strategic alliances with Celgene Corporation, Bayer Pharma AG and GlaxoSmithKline (GSK). Additional information can be found at the company's website: www.oncomed.com.
CONTACT: Media & Investors OncoMed Pharmaceuticals Michelle Corral Senior Director, Investor Relations and Corporate Communications email@example.com (650) 995-8373 Investors Shari Annes Annes Associates firstname.lastname@example.org (650) 888-0902
Source:OncoMed Pharmaceuticals, Inc.